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Herbal Medicines Registration Process for Zimbabwe Overview
of the Process
J. Usai 1, Z. Ekeocha 2, S. Byrn 3, K. Clase 4
ABSTRACT
Unregistered traditional medicines pose a huge public health threat as the safety and efficacy of these products is
unknown. The issue this study addresses is the inadequate regulatory measures for herbal medicines in
Zimbabwe. This project was done to describe the current registration process of traditional medicines in Zimbabwe,
and to identify the gaps and opportunities they present to improve the regulatory landscape. Regulations and laws
governing the registration of herbal medicines in the country and published research on legislation of herbal
medicines were reviewed. Two parallel regulatory bodies both registering and controlling the sale of herbal
medicines were identified. The Medicines Control Authority of Zimbabwe (MCAZ) and the Traditional Medical
Practitioners Association (TMPA) both derive their authority to regulate from the ministry of health and were
established through the act of parliament which gives these authorities power to regulate the quality and sale of
traditional medicines without giving a prescriptive way of doing it. The registration process, and product evaluations
for the two authorities are different. While the MCAZ has a clearly defined registration process, the TMPA does
not. However, MCAZ has not been very successful in registering local products with the majority of the registered
herbal products being imports and only 2% of total registered products being local herbs. As a recommendation,
there is need for collaboration between the regulatory bodies for consistence in quality of herbal products on the
market and to improve registration of local herbal products. Developing monographs for local herbs commonly
used in the country will also assist local manufacturer to fulfill the quality requirements and successful compilation
of dossiers for product registration.
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DEFINITION OF TERMS
Herbal medicines: These are medicines of plant origin
used for treatment, diagnosis or management of
disease and other ailments in humans. They contain
processed or raw plant materials from one or more
plants. Herbal medicines can also be referred to as
traditional medicines or complementary medicines
(WHO, 2005).
Traditional medicine: It is the combination of skills,
knowledge and practices grounded on cultural
experiences, theories and beliefs applied in the
management of health (WHO, 2005).
Regulation: The building structure for execution of
policies and proposes a method for registering herbal
products.
1. INTRODUCTION
The use of herbal products medicines in Africa is a
common practice. About 80% of people on the African
continent depend on herbal medicines for their
primary health care needs (WHO, 2005). This has
been attributed to easy accessibility, low cost and a
longstanding history of effectiveness and safety. Use
of herbal medicines forms the origin of medicine with
many conventional drugs originating from plant
source (Pal & Shukla, 2003). Some drugs are plantbased, such as Aspirin (from the willow bark), digoxin
(from the fox glove), quinine (from the Cinchona bark).
However, there have been major safety issues arising
from the use of unregistered traditional medicines
whose safety and efficacy have not been evaluated.
In Zimbabwe traditional medicines represent the
biggest single group of poisoning cases (23%), with
the majority of patients being children younger than 5
years old (53%) (Nhachi & Kasilo, 1992). A high
mortality rate has been associated with poisoning
from traditional medicines (Tagwireyi et al., 2002).
Severe adverse events from herbal supplements
have shown the harm associated with unregulated
herbal medicines (Maphosa et al., 2013) as these
medicines may be contaminated with poisonous
chemicals, heavy metals and endogenous toxins.
Herbal medicines prepared from extracts of plants
such as Euphobia, Solanum and Datura species have
been found to contain toxic agents (Tagwireyi et al.,
2002). It is against this background that regulation
and quality assurance standards are pivotal in
promoting access to safe and efficacious traditional
medicines. However development and enforcement
of policy and regulations for herbal medicines is a
challenge in African (WHO, 2019).

The current global market for herbal products is 60
billion and is expected grow at CAGR of 7.2%
(Carvalho, 2020). Multinational companies have also
gained interest in the market for herbal medicines
(Mukherjee & Houghton, 2009). Herbal products form
an important part in primary health care. However,
product assessment and quality assurance of these
products are a huge stumbling block in product
development. As the demand and use of herbal
medicines is increasing globally, more public health
concerns associated with safety of these products are
emerging. A number of challenges hinder improved
regulation of herbal medicines. These include
absence of efficient quality control in the production
processes, absence of good distribution practice
within the supply-chain including traceability, lack of
proper identification of botanical species, and no
characterized markers or active constituents
(Mukherjee & Houghton, 2009).
The increasing demand, the rising economic value
and adverse effects of herbal products have prompted
health ministries to develop laws that will ensure safe
use of these products (Alostad et al., 2018). Some
countries like Austria, France and Germany have
legislated well-defined registration systems for herbal
products (Fan et al., 2012), while other nations are still
struggling to develop and enforce laws on regulation
of herbal medicines. The absence of registration and
evaluation of herbal products has detrimental effects
on public health. In some markets, such as the US for
example, herbal medicines are regulated under
dietary supplements and are not required to undergo
premarket evaluation by the FDA. Reports of
counterfeit herbal products and adverse events from
these products have been observed (Fan et al.,
2012). In the US, dietary supplements and herbal
medicines accounted for 15.5% of hepatotoxicity
events (Fontana et al., 2009). A 2013 study in Toronto
analyzed 44 herbal products from US and Canada
markets. This study found that less than 50% of the
products contained the herbal medicine on the label
claim; and more than 50% of the supplements had
extra ingredients not mentioned on the label
(Newmaster et al., 2013). Therefore, it is crucial for
nations, where herbal medicines are consumed, to
design a registration system for herbal medicine
products and ensure that they are evaluated for
quality, efficacy and safety before they go to the
market. However this is the primary difficulty in
registering of herbal medicines because of the
chemical complexity of herbs. The registration
process must be simple and should not delay product
registration. The registration process must specify
product evaluation criteria which includes safety,
efficacy and quality. The evaluation criteria should
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also include stability testing, packaging and labeling.
Quality is the standard of a medicinal product
measured against purity, its identity and product
content. It can be influenced by the production
process, other chemical, biological and physical
properties. Quality control is the process of ensuring
quality of the finished product. Botanical identification
and verification is the initial step in quality assurance,
it ensures that the right plant and the correct part/s is
used. The manufacturer is expected to provide: Latin
binomial and vernacular names, plant part/s used for
the product, and a comprehensive description for
plant production and harvest conditions in accordance
to in-country good agricultural practice (WHO, 2000).
For identity most regulatory authorities rely on local
herbarium.
Assessment of herbal medicines is very difficult due
to chemical complexities of the product. For most
herbal drugs, the active ingredient is unknown,
making
assay/content
evaluation
challenging
(Bandaranayake, 2006). Markers compounds are
commonly used in content or assay of herbal
products. These are chemical constituents of herbal
products which are chosen for quality control
purposes to ensure product consistency and assist in
assay. The marker may or may not have therapeutic
effect. The European Medicines Agency (EMA)
defines markers elements as chemical elements, or a
group of constituents, used for quality control
purposes of herbal products regardless of their
therapeutic effect. Markers are very important in
quality control. They aid in
ensuring content
uniformity and product standardization in herbal
products. Choice of markers is based on chemical
stability, how easy it is to analyze, cost and time of
analysis, relation to product efficacy and
quality/stability. (Mukherjee & Houghton, 2009).
Ideally a herbal product chemical marker should be a
trait constituent and must be therapeutically
significant however for most herbal products
therapeutic components are unknown. Though
markers may not have pharmacological activity, their
presence in the plant material is set, with specific
chemical
attributes
(Bandaranayake,
2006).
Srinivasan classifies markers into four group as
shown in table 1 based on their chemical attributes.
The constituents of the marker chemicals is directly
affected by any slight change in the quality of the
herbal material.
Therefore, the quantitative and qualitative analysis of
marker compounds is a reliable quality control
protocol.

Table 1. Classification of marker elements
(Srinivasan., 2006)
Classification
Active principles

Known therapeutic
effect

Active markers

Contribute to
therapeutic effects

Analytical markers

No therapeutic or
pharmacological
importance. They aid in
positive identification

Negative markers

Possess toxic or
allergenic properties. A
stringent limit of these
markers maybe
specified.

Published herbal monographs in pharmacopeias play
a crucial role in quality control of herbal products.
They set the quality control standards for both the
manufacturers and the regulators. They help define
the minimum quality standards and purity
requirements that form the basis for qualitative
evaluation and assessment of herbal product for
market approval. While some countries have
developed pharmacopeia monographs to aid in the
registration
of
herbal
medicines:
British
pharmacopeia, European pharmacopeia and the
Indian pharmacopeia (Mukherjee & Houghton, 2009),
some countries have not. Where there are no
published pharmacopeial monographs, analytical
procedure development and method validation are
the manufacturer’s responsibility (Bandaranayake,
2006). A significant variation of pharmacopeial in
quality standards and plant specific parameters has
been noted among different countries. This may be
attributed to varying chemical constituents of the
plants due to climate and environmental variations.
For a country with establish herbal monographs,
quality standards for the indigenous herbs are well
defined and the information is made readily available
for manufacturers and regulators, which goes a long
way in improving herbal medicines registration. This
project will investigate how Zimbabwe’s regulatory
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authority is setting standards for quality evaluation
and what technical documents exist to aid
manufacturers in quality control.
Table 2. Common herbal medicines contaminants (WHO, 2007)

Chemical contaminants
Heavy metals

Mercury
Lead
Cadmium
Arsenic
Chromium

Microbial contaminants

Micro-organisms

Fungi
Parasites
Bacteria

Residual organic solvents
Methanol
Acetone
Ethanol
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It is very difficult to produce a 100% pure herbal
product; the product is often contaminated. Table 2
shows possible contaminants for herbal products.
Common contaminants can be classified as chemical
contaminants, microbial contaminants and residual
solvents used in the production or extraction
processes. Herbal medicines should be evaluated for
contamination and should not exceed specified limits
set bey the national regulatory authorities.
Quantitative and limit test can be used to evaluate the
level of contamination. The choice of test for
determination of contaminants is determined by the
nature of the impurity and the type of sample to be

analyzed. Regulatory authorities can choose to use
either quantitative or limit tests based on this
consideration. Procedures used to determine toxic
metal contamination should meet the national and
regional regulatory requirements and they should be
relevant. The best strategy in quality control is to
abide by the pharmacopeal definition of purity, identity
and content. Table 3 shows examples of proposed
limits on heavy metal contamination.

Table 3. Proposed limits on heavy metal contamination (WHO,2007)

Mercury

Lead

Chromiu

Arsenic

Cadmium

m
Malaysia (mg/kg)

0.5

Thailand (ppm)

10

5

10

4
5

Singapore (ppm)

0.5

20

Canada (mg/day)

0.02

0.02

WHO

0.02

10

0.01

0.3

0.006
0.3

recommendation
(mg/kg)

There is a great need for the product registration
system to control labeling of herbal medicines, as it is
the primary and, sometimes the only, source of
information about the product from the manufacturer
to the consumer. The quality of information presented
about the herbal product is equally important as
product quality. Properly labeled products reduce the
incidence of inappropriate drug use and adverse drug
events (Bandaranayake, 2006). WHO (2010)
recommends the labelling information to include
1. Name of the product

2. Indication of use
3. Storage conditions
4. Expiry date or product shelf life
5. Contraindication and any other warnings
6. Directions of use,
7. Manufacturer, packer or distributor’s name
and address,
8. Quantity per dosage unit
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9. List of any other ingredients and additive.
A Singapore study identified labeling inconsistency,
false label claim and missing important product
information as problems commonly encountered in
herbal medicine labeling (Yee et al., 2005). Some of
the labeling shortcomings identified during herbal
product registration included:
1. For most products imported from Asia, the
products were not labeled in English. In some
instances, the English translation on crucial
product information (product indication and
dosage, for example) did not match the
original text.
2. Batch number and expiration date were not
stated and, in some cases, unrealistically
long shelf life stated without scientific
justification.

•

evidence of longstanding
experience of product use;

history

and

•

indications the product was used for;

•

historical and ethnographic background of the
product.

A herbal product is considered safe if there is
documented evidence of traditional use without any
reported adverse events and there are no restrictive
regulatory requirements for such a product (WHO,
2000). A thorough literature review of all available
information about the plant medicine should be
conducted. This should include original research
articles, oral evidence and references. Available
review articles and monographs should be analyzed
too (Ameh et al., 2010). Table 4 summaries
documentation of safety based on experience.

3. Inadequate information was provided on
primary ingredients or any other controlled
substances.
4. Ingredients were improperly named.
5. Quantity of active ingredient was not stated.
6. Directions of use were not properly presented
and some deviated from what was approved
in the country of origin and the standard
formulary.
7. False or exaggerated therapeutic claims were
made. The claims were prohibited in the
country of origin.

Table 4. Documentation of safety based on
experience (Ameh et al., 2010)
Condition
No toxicological
exist

8. Information on contraindications and side
effects of the herbal product were not
provided ( Yee et al., 2005).
In relation to medicines, safety can be defined as the
probability of not causing trauma when used as
prescribed. Efficacy is the ability to produce a medical
benefit. When evaluating whether the herbal product
is safe and effective, the therapeutic indication has to
be considered. A herbal product is only useful if it is
both safe and effective (Moreira et al., 2014). In some
European countries safety and efficacy evaluation of
herbal medicines can be based on proof of
longstanding history of product use and traditional
experiences while other countries may require a form
of clinical studies. In US herbal medicines are only
recognized as safe when they meet modern medicine
standards, in which case they can be registred as a
drug. Otherwise they are not considered medicines
and regulated as dietry supplements. A longstanding
history of product use, defined as a period of use from
20 to 30 years, although it varies between cultures,
experience is key in evaluating safety and efficacy of
herbal products. It considers:

Action needed
data Assess risk based on
documented evidence of
traditional
use
and
experience (for a period
of at least 20yrs) without
any reported adverse
events. Period of drug
use must be considered.

Some toxicological data Document
condition/s
exist
treated, figure of treated
patients and place of
treatment.
There is toxicity

Try to show relation to
dose administered.

There is potential for Document all misuse
misuse
and dependence cases.
There is no proof of Long Toxicological
studies
term tradition use.
should be done.
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The key points for assessment of efficacy of a herbal
medicine are:
1. Are the product ingredients, and their
phamacodynamic properties well defined?
What is the link with the observed clinical
outcomes?
2. Is the therapeutic application for the product
specified? What proof supports the
indications of use? There is need to
thoroughly look at the evidence that supports
the therapeutic claims.
3. Clinical evidence for products without
established long-term traditional use (Ameh
et al., 2010).
The evaluation criteria for efficacy recommends that
both the therapeutic and pharmacodynamics effects
and the active ingredient be named or specified if
known.
The global requirements for proof of
effectiveness can be less stringent for herbal products
used to treat minor ailments or for prophylaxis,
considering the history of traditional use. Documented
experiences from traditional practitioners and
physicians should be considered (WHO, 2000). For
most regulatory authorities for example Brazilian
National Health surveillance agency and EMA safety
and efficacy is evaluated based on evidence of long
term use. If a product fits in the definition of long
standing traditional use data from clinical or preclinical studies is not a prerequisite to obtain approval
for commercialization (Moreira et al., 2014).
In response to the growing threat of unsafe traditional
medicines, studies have been done to build on
identity, pharmacological properties of various plants
and to document the traditional knowledge on
effective herbs and their use in an attempt to preserve
traditional knowledge (Maroyi, 2013). Research has
also been done to identify toxicity associated with
traditional medicines. These studies all point to the
need of effective regulatory systems that adequately
assess and evaluate all traditional medicines to
ensure provision of quality, safe and effective
traditional products in the country. In 2010 the
Zimbabwe
parliament
health
committee
recommended the creation of a regulatory framework,
as well as guidelines, for traditional medicines. World
Health Organisation (WHO) has been advocating and
promoting the need for access to safe, effective and
quality herbal medicines (WHO, 2013).
An efficient and effective registration system of
traditional medicines is key in ensuring safety, quality
and effectiveness of traditional medicines. In its 20142023 strategy for traditional medicines, WHO
endeavors to strengthen quality control, promote safe,

correct use and efficacy of traditional medicines by
controlling traditional products and practices (Qi,
2013). To achieve this goal, product registration is key
(Qi, 2013). Regulation of traditional medicines
presents a number of challenges. Studies have been
done to analyze the registration process of these
products in various countries to try and improve
product regulation. These include a case study on
Bahrain and Kuwait traditional medicine registration
systems and policy implementation (Alostad et al.,
2019) and Global perspective of traditional medicines
regulation and variations between countries (Fan et
al., 2012). These studies examined the regulatory
framework with emphasis on the registration process
in an effort to improve regulation of herbal products.
However due to variations in traditional medicine
practices in various cultures, herbal medicines
regulatory challenges and experiences are not the
same. Therefore there is a need to study the
registration process of herbal medicines in Country A
with a background of the unique cultural beliefs and
practices of traditional medicines in the country.
About 80% of people in country A use herbal products
for their primary health care needs. In spite of the
support and efforts towards regulation of herbal
medicines, there are still a huge number of
unregistered herbal medicines used in the country,
presenting a huge public health problem of safety and
quality. This project aimed to discover the challenges
and obstacles affecting the registration of herbal
products in the country.

Key concepts
Table 5. Reasons for increase in unregistered
herbal products in the market of Zimbabwe
1. There are no adequate laws and regulations
2. The registration process is not well defined
3. Manufacturers and wholesalers are finding the
registration process difficult to follow
4.There is no surveillance of traditional medicines in
the market by regulatory authorities to enforce the
law
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2. METHODS
The following document were reviewed:
1. 2019 complementary medicines register for
Zimbabwe to come up with:
•

Registrations trends

•

Total number of complementary
medicines registered

•

Imported herbs versus local herbals

•

Country and manufacturer of the
registered herbal medicine.

application
application / "
submission
submission
C

Dossier
Dossier
"
evaluation
e_v_a_Iu_a_t_io_n_,/

_ _ _

Figure 1. MCAZ herbal products registration process

For the registration process in Zimbabwe a complete
application consists of
1. Dossier

2. The guidelines on document submission for
herbal medicine registration in Zimbabwe to
determine the herbal medicines registration
process, product evaluation criteria, labeling
requirements, and prohibited indications.

2. Application fees

3. Published research on traditional medicines

4. Completed C.M 1 form.

4. WHO guidelines on registration of traditional
medicines were also analysed and compared
to the country registration process to identify
gaps.

5. Declaration by the applicant

5. The Traditional Medical Practitioner’s Act
Chapter 27 and the Complementrary
Medicines
Regulations
medicines
regulations.
3. RESULTS AND DISCUSSION
Two regulating bodies were identified: the Medicines
Control Authority of Zimbabwe (MCAZ) and the
Traditional Medical Practitioners Association (TMPA).
Both authorities derive their power to regulate from
the act of law, MCAZ from statutory instrument 97 of
2015 and the TMPA from Traditional medical
practitioners act chapter 27:14. The two are not
interrelated. The major differences of the two
authorities are highlighted in Table 6. MCAZ has a
well-documented registration process shown in
Figure 1. No published registration process for TMPA
was identified.

markert
markert
authorisation
authorisation/

3. Product samples, submitted in their original
container as intended for the patient. The
sample should be labeled as it will be on the
final product.

The samples should be accompanied by a copy of
certificate of analysis, product specifications and
analytical methods. The applicant should provide
reference standards, degradation products and
related impurities for a full monograph analysis. The
samples should be labeled as the final product
planned for the market.
MCAZ evaluators assess the dossier while inspectors
evaluate company conformance to current Good
Manufacturing Practices (GMP). Any company
manufacturing herbal medicines is required to adhere
to some cGMP standard. The applicant is required to
provide supporting evidence which demonstrates
their compliance. The inspectors may conduct GMP
inspection before product registration. Analysists test
the samples supplied. When a product meets all the
regulatory requirements it is then registered as either
a complementary medicine for general sale or
pharmacy complementary medicine. Products
registered as pharmacy complementary medicines
can only be sold in a pharmacy. There are no
restrictions on sale of complementary medicines
general sale.
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Local
herbs,
2%

Importe
d herbs,
98%
Figure 2. Compares registered local herbal products vs Imported herbal products

Table 6. Comparison of the Herbal medicine registration Process of TMPA and MCA in Zimbabwe
TMPA

MCA

The practitioner has to be registered as a
member of the TMPA before they can sell their
products

No affiliation to anybody or association is required

No defined registration process

A clearly defined registration process

No clearly laid out evaluation procedure for
effectiveness, safety and quality

Detailed evaluation procedure
effectiveness and quality

Products are sold through herbal drug stores

Products are sold in registered retail pharmacies

Derive the authority to regulate traditional
medicines from the Traditional Medical
Practitioners Act chapter 27.14

Mandated by the ministry of health through statutory
instrument to regulate all complimentary medicines

MCAZ registers herbal medicines as complementary
medicines. According to the December 2019
complementary
register,
there
were
195
complementary products registered by the MCA with
the majority being imported product (98%) and a very
small percentage (2%) were local herbs, as shown in

for

safety,

Figure 2. Therefore this process is not addressing the
health risk posed by the local products, which are the
bulk of the herbal products being consumed in the
country.
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MCAZ regulates all complementary medicines
except those compounded, dispensed and
administered by the practitioners in their practices at
their premises. Some regulatory agency follow a twotier system for herbal medicines registration. This is
a risk based approach allowing early market
authorizat for products containing low risk
ingredients and manufactured in accordance with
GMP. These products are mainly used for health
maintains and health enhancement or self-limiting
conditions (Fan et al., 2012). European Medicines
Agency
(EMA),
Australian
Complementary
Medicines Registration Agency and Brazilian
Regulatory Authority have a two-tier registration
processes for herbal medicines. In contrast to other
regulatory authorities with two-tier registration
processes, a risk based registration process, all the
MCAZ registered herbal products follow the same
process highlighted in Figure 1. Considering that in
developed countries, stricter guidelines affect wellestablished herbal products manufacturers, in Africa
it is the traditional medical practitioners who will have
to comply with these regulations. Thus, there is a
need to minimize the registration requirements, while
having the best possible impact on protecting
consumers (Ngcobo et al., 2012). Reduction in
bureaucracy by introducing a risk-based approach
based on risk assessment and intended use might
aid in improving local registrations. An example of
this is the Brazil approach where herbal medicines
are classified into two categories: herbal medicines
and traditional herbal medicines. Herbal medicines
are registered after providing proof of safety and
effectiveness, through clinical and non-clinical trials.

Traditional herbal medicines are registered through
known history of traditional use. While herbal
medicines have to be registered before marketing,
traditional medicines can be notified. Notification is
simple market authorization process meant to reduce
bureaucracy in registration of herbal products
manufactured by GMP compliant authorized
companies, following a well laid out technical
procedure. For a traditional medicine to qualify for
notification it has to be in the Brazilian Herbal
formulary and preparation must have a quality
assurance monograph in an official pharmacopeia
(Carvalho et al., 2018). MCAZ may consinder the
risk-based approach in their registration process for
herbal medicines as a way of promoting registration
of indigenous herbs. This will allow early market
access to local herbal products that have a low risk
to the public.
The MCAZ evaluation for herbal medicines is based
on quality, safety and effectiveness. Safety and
efficacy evaluation is evidence-based. Toxicological
and clinical studies are not a prerequisite if the
product is used for the same known indication.
Clinical studies are required for new indications. The
process used to evaluate safety and efficacy of
herbal medicines by MCAZ was compared to the
evaluation process used by other regulatory
authorities (Table 7). Some regulatory authorities
such as EMA define traditional use as a documented
period of use of 30 yrs with at least 15 years of use
in the European union. Unlike other regulatory
authorities like EMA, MCAZ does not have a defined
period of use as a prerequest for product registration.
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Table 7. Comparison of registration process of herbal medicines in Zimbabwe by MCAZ and other countries regulatory
authorities (Fan et al., 2012; Ngcobo et al., 2012)
Requirements for
registration

EMA

TGA Australia

Identify all the
ingredients used in
product formulation.
Pharmaceutical
quality

Raw materials
specified by botanical
identification. Quality
prerequisites similar
to conventional
medicines

Identify the part/s of
plant used and any
processing done
prior product
manufacturing

WHO Guidelines for
registration of traditional
medicines in Africa

MCAZ
guidelines for
complementary
medicines
registration

Characterization of plant raw
materials, stating the part/s
used. Quantitative and
qualitative analyses of the final
herbal product. Purity test to
exclude toxic metal and
microbe contaminants.

Botanical
identification by
herbarium of the
country of
origin.
Qualitative and
quantitative
tests of plant
materials. Purity
tests to exclude
toxic metal and
microbe
contaminants.

Provide a summary
of the production
process.

Safety

Therapeutic efficacy

Based on
documented evidence
of safe traditional use.
To included
information on safe
use in pregnancy and
lactation. Mention
probable interactions
with other drugs.

Evaluation based on
evidence of safe
traditional use.
Manufacturer to
provide information
on safety of product
in pregnancy and
lactation. To include
herbal ingredients
and any probable
interactions with
other drugs

Evaluation based on
evidence of long
standing use and
experience.

Evaluation based on
historical evidence of
long standing use.
Evidence from
clinical studies is
required when there
is no history or
enough evidence of
traditional use.

Botanical certification of plant
material; literature search for
biological data.

Toxicological studies are a
must.

Evaluation depends on the
type of indication for use and
traditional medical
practitioners and physicians
experiences. Data from clinical
trials required to support new
indications.

Botanical
identification by
herbarium of
country of
origin. Evidence
based, no
clinical trials
toxicological
studies if the
product has
proven safe
traditional use
and will be used
for the same
indication, same
dosage form
and dose.
Evaluation
depends on the
type of
indication for
use and
traditional
medical
practitioners
and physicians
experiences.
Clinical data is
needed when
the product is
used for a new
indication, in the
absence of
documented
evidence.
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Labeling and
packaging

Product should be
clearly labeled and
easy to read by the
targeted users and
should have a
package insert with all
the required
information on
product use,
indication, dosage,
storage conditions,
shelf-life, batch
number and
contraindications.

Product should be
clearly labeled, with
all the required
information
according to
Australian TGA
1989. labeling
guidelines

In Zimbabwe evaluation of the quality of traditional
medicines is based on three pillars: identity, purity
and content. The MCAZ quality control test
requirements include test for heavy metals, microbial
contamination and adulteration. For identification
MCAZ relies on the herbarium of the country of origin
of the herb. The manufacturer or applicant has to
submit a certificate of identity from their local
herbarium.
Globally quality control of herbal medicines still
remains a challenge, as sometimes the active
ingredients might be unknown or there may be
multiple ingredients. This is more often the case for
herbs that are not thoroughly studied, especially
most African herbs. An applicant or manufacturer is
to submit monograph specifications and tests
performed, according to their chosen pharmacopeia,
or submit their in-house validated methods for assay.
As there are no national monographs or
pharmacopeia for herbals in country A, developing
inhouse tests for quality control can be challenging,
especially for local manufacturers. Globally in the
registration process, quality seems to be most
difficult even with well-established and experienced

Packaging and labeling
requirements are part of GMP
and quality control

Similar to
conventional
medicines.

manufactures and regulators (Fan et al., 2012).
Monographs play a critical role in the registration
process of herbal medicines. They help establish
quality control standards by defining identity, quality,
strength, and purity standards of the herbal product.
Development of herbal monographs were they do
exist would benefit both the regulators and local
manufacturers in ensuring quality herbal product
registrations (Qu et al., 2014). It was observed that
the majority of the products (93.5%) registered by
MCAZ are imported from countries with developed
national herbal medicines compendiums and
pharmacopeias, which makes it easier for foreign
manufacturers with access to compendia and
pharmacopeia to comply the information required by
the authorities. An example is the British herbal
compendium, which has monographs for herbs.
Monographs start with definitions and synonyms and
the botanical information, followed by a detailed
description of the established herbal constituents. It
also provides information on quality control and
references assay methods. This is critical in
evaluation of herbal products (Bradley, 2006).
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Table 8. Comparison of Technical standards and developments in herbal medicines regulations (Fan et al., 2012;
Sahoo, Manchikanti, & Dey, 2010)

Country

Bangladesh

Herbal drug
registration
system

Exist

National
monograph

Pharmacopeia

Percentage of
Products
registered in
Zimbabwe

Does not exist

Bangladesh national
formulary on Unani
and Ayurvedic
medicines

4%

34%

India

Exist

Does not exist

Ayurvedic
pharmacopeia of
India and Unani
pharmacopeia of
India

United Kingdom

Exist

British herbal
compendium

British herbal
pharmacopeia

11.20%

USA

Exist

USP herbal
medicine
compendium

USP pharmacopeia

16.20%

Zimbabwe

Exist

No

No

1%

Table 8 summarises the resources and technical
documents in Zimbabwe versus other selected
countries whose products are registered with the
MCAZ. India, the biggest importer of herbal
medicines to country A, has the highest product
registration 34% and does have national formulary,
compendium and a pharmacopeia for herbal
medicines. Australia, United Kingdom and the US
also have these national resources. Local
manufacturers in Zimbabwe might struggle to fulfill
the requirements for the country’s registration
process, due to limitations on the avalibe resources.
There are no local herbal monographs.
MCAZ is restrictive in product claims for herbal
medicines. It has a list of prohibited medicinal claims
which include: cardiovascular indication (e.g.
hypertension and hypotension), HIV-AIDS, cancer,
sexual transmitted infections, tuberculosis, diabetes,
kidney stones, prostate gland disorders, rheumatoid
arthritis, infantile diarrhea, epilepsy, Parkinson’s
disease and meningitis. Evidence has shown
effectiveness and wide use of herbal medicines on
some of the prohibited indications, such as sexual
transmitted infections. Sexual transmitted infections
are one of the primary reasons people consult
traditional medical practitioners in country A, as there

are plants that have been shown to be effective
therapy (Maroyi, 2013). This could be a deterrent for
registering such local herbal products. To promote
registration of these products, MCAZ could allow
registration of these products based clinical trials or
document clinical evidence.
4. CONCLUSION
Regulation of herbal medicines in Zimbabwe is still
in its infancy stage and there is a need to build on
the already established structures and efforts of
MCAZ. While the well-defined registration process
is able to register imported herbal products in the
country, it is missing the local herbs, which is what
the bulk of the population are consuming.
Collaboration between the MCAZ and the TMPA will
improving local herbal medicines legislation. While
TMPA has wealthy of knowledge and experience
with use of herbal medicines and the practice of
traditional medicine they may benefit from the
experience and expertise of MCAZ in control and
regulation of medicines. MCA has expertise and
experience in legislation of medicinal products.
They ensure compliance to quality control standards
and good manufacturing practice. Jointly the two
bodies can effectively regulate the sell of herbal
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medicines, learning from each other’s unique
knowledge and expertise in herbal medicines use
and production.
All herbal medicines registered by MCAZ follow the
same procedure. There is a need for a risk-based
approach in product registration. MCAZ could
emulate other regulatory authorities and consider a
more simplified approached for their local traditional
medicines, based on intended use and the
toxicological profile of the herb. This will reduce
bureaucracy, thus saving time for the regulators and
improve registration of local herbal products.
There is no local herbal medicine compendium to
define the quality standards, tests and specifications
for local herbs, therefore the manufacturers of local
herbal medicines developed their own methods and
specifications to prove product consistency and
quality which could be a huge task, considering the
expertise and knowledge of most traditional
practitioners. There is a need for developing herbal
medicines compendium and a pharmacopeia for the
country’s herbal medicines with monographs. This
will assist in setting up quality standards that are
achievable by local manufacturers.
5. RECOMMENDATIONS FOR NEXT STEPS
There is a need for collaboration between the two
regulatory bodies; together they can achieve more
and
learn
from
each
other.
The MCAZ may benefit from the practice of other
regulatory authorities by applying a risk-based
approach in regulation of low risk local herbal
products to create a more simplified process.
Development of monographs, compendiums for local
herbs by Zimbabwe will assist in setting quality
standards which are internationally acceptable. The
compndiums will be a guide for the local
manufacturers to produce quality herbal products
which are safe and efficacious. It will make it easier
for them to follow in order to compile the required
information for dossier submissions.
REFERENCES
Alostad, A. H., Steinke, D. T., & Schafheutle, E. I.
(2018). International comparison of five
herbal medicine registration systems to
inform regulation development: United
Kingdom, Germany, United States of
America, United Arab Emirates and
Kingdom of Bahrain. Pharmaceutical
medicine, 32(1), 39-49.

Alostad, A. H., Steinke, D. T., & Schafheutle, E. I.
(2019). A qualitative exploration of Bahrain
and Kuwait herbal medicine registration
systems:
policy
implementation
and
readiness
to
change.
Journal
of
pharmaceutical policy and practice, 12(1),
32.
Ameh, S. J., Obodozie, O. O., Inyang, U. S.,
Abubakar, M. S., & Garba, M. (2010).
Current phytotherapy-A perspective on the
science and regulation of herbal medicine.
Journal of Medicinal Plants Research, 4(2),
072-081.
Bandaranayake,
W.,
M.
(2006).
Morden
phytomedicine, turning medical plants into
drugs. In I. Alamad, F. Qil, & M. Owasis
(Eds.), Quality control screening, toxicity and
regulation of herbal drugs (pp. 25-34).
Bradley, P. (2006). British herbal compendium.
Volume 2: a handbook of scientific
information of widely used plant drugs.
British herbal compendium. Volume 2: a
handbook of scientific information of widely
used plant drugs.
Carvalho, A. C. B., Lana, T. N., Perfeito, J. P. S., &
Silveira, D. (2018). The Brazilian market of
herbal medicinal products and the impacts of
the new legislation on traditional medicines.
Journal of Ethnopharmacology, 212, 29-35.
doi:https://doi.org/10.1016/j.jep.2017.09.040
Carvalho, J.C.T., Market analysis on traditional
medicine-2020. Herbal Medicine: Open
Access, 6(2).
Fan, T.-P., Deal, G., Koo, H.-L., Rees, D., Sun, H.,
Chen, S., . . . Chan, K. (2012). Future
development of global regulations of
Chinese herbal products. Journal of
Ethnopharmacology,
140(3),
568-586.
doi:https://doi.org/10.1016/j.jep.2012.02.029
Fontana, R. J., Watkins, P. B., Bonkovsky, H. L.,
Chalasani, N., Davern, T., Serrano, J., . . .
Group, D. S. (2009). Drug-induced liver
injury network (DILIN) prospective study.
Drug safety, 32(1), 55-68.
Govindaraghavan, S., & Sucher, N. J. (2015). Quality
assessment of medicinal herbs and their
extracts: Criteria and prerequisites for
consistent safety and efficacy of herbal
medicines. Epilepsy & Behavior, 52, 363371.
doi:https://doi.org/10.1016/j.yebeh.2015.03.
004
Jayaraj, P. (2010). Regulation of traditional and
complementary medicinal products in
Malaysia. International Journal of Green
Pharmacy (IJGP), 4(1).

15
Maroyi, A. (2013). Traditional use of medicinal plants
in south-central Zimbabwe: review and
perspectives. Journal of ethnobiology and
ethnomedicine, 9(1), 31.
Moreira, D. d. L., Teixeira, S. S., Monteiro, M. H. D.,
De-Oliveira, A. C. A. X., & Paumgartten, F.
J. R. (2014). Traditional use and safety of
herbal medicines1. Revista Brasileira de
Farmacognosia,
24(2),
248-257.
doi:https://doi.org/10.1016/j.bjp.2014.03.006
Mukherjee, P. K., & Houghton, P. J. (2009).
Evaluation of herbal medicinal products :
perspectives on quality, safety, and efficacy.
London ; Chicago: Pharmaceutical Press.
Newmaster,
S.
G.,
Grguric,
M.,
Shanmughanandhan, D., Ramalingam, S., &
Ragupathy, S. (2013). DNA barcoding
detects contamination and substitution in
North American herbal products. BMC
medicine, 11(1), 222.
Ngcobo, M., Nkala, B., Moodley, I., & Gqaleni, N.
(2012).
Recommendations
for
the
development of regulatory guidelines for
registration of traditional medicines in South
Africa. Afr J Tradit Complement Altern Med,
9(1), 59-66. doi:10.4314/ajtcam.v9i1.9
Nhachi, C. F. B., & Kasilo, O. M. J. (1992). The
pattern of poisoning in urban Zimbabwe.
Journal of Applied Toxicology, 12(6), 435438.
Pal, S. K., & Shukla, Y. (2003). Herbal medicine:
current status and the future. Asian pacific
journal of cancer prevention, 4(4), 281-288.
Qi, Z. (2013). Who traditional medicine strategy
2014-2023.
Geneva:
World
Health
Organization.
Qu, L., Zou, W., Zhou, Z., Zhang, T., Greef, J., &
Wang, M. (2014). Non-European traditional
herbal medicines in Europe: A community
herbal monograph perspective. Journal of
Ethnopharmacology,
156,
107-114.
doi:https://doi.org/10.1016/j.jep.2014.08.021
Sahoo, N., Manchikanti, P., & Dey, S. (2010). Herbal
drugs: standards and regulation. Fitoterapia,
81(6), 462-471.
Srinivasan, V.S. (2006). Challenges and scientitic
issues in standardization of botanicals and
their
preparations.United
States
Pharmacopea’s
dietary
supplement
verification program- A public health
program. Life sciences, 78(18), 2039-2043.
Tagwireyi, D., Ball, D. E., & Nhachi, C. F. B. (2002).
Traditional medicine poisoning in Zimbabwe:
Clinical presentation and management in
adults. Human & experimental toxicology,
21(11), 579-586.

WHO. (2000). General Guidelines for Methodologies
on Research and Evaluation of Traditional
Medicine. Retrieved from geneva:
WHO. (2005). national policy on traditional medicine
and regulation of herbal medicines.
Retrieved from geneva:
WHO. (2007). WHO guidelines for assessing quality
of herbal medicines with reference to
contaminants and residues. In. 2007: World
Health Organisation.
WHO. (2019). WHO global report on traditional and
complemntary medicine 2019. Retrieved
from geneva:
Yee, S.-K., Chu, S.-S., Xu, Y.-M., & Choo, P.-L.
(2005). Regulatory control of Chinese
Proprietary Medicines in Singapore. Health
Policy,
71(2),
133-149.
doi:https://doi.org/10.1016/j.healthpol.2003.
09.013
Zhang, J., Wider, B., Shang, H., Li, X., & Ernst, E.
(2012). Quality of herbal medicines:
challenges and solutions. Complementary
therapies in medicine, 20(1-2), 100-106.
ACKNOWLEDGEMENTS
I would like to thank all of the BIRS guest faculty from
global industry and regulatory organizations for
generously sharing their professional expertise and
providing donated, in-kind time towards building the
professional skills and technical capabilities of the
students within the BIRS program. I would also like
to thank my fellow peers in the BIRS MS student
cohort for providing guidance and constructive
feedback during the classroom group work and
interactive sessions; Abigail Ekeigwe and Mercy
Okezue, Purdue ABE BIRS PhD candidates, for their
mentorship and input throughout the project;
Professor Fran Eckenrode for providing content
expertise throughout the review process on this
paper; and Lauren Terruso, operations manager for
BIRS Center, for all of her efforts on editing multiple
iterations of the technical paper draft in preparation
for publication. The international component of the
Purdue BIRS program was initiated through
educational support provided by the Merck
Foundation and most recently through a capacity
building effort funded by the Bill and Melinda Gates
foundation, grant # 41000460.

